[A21-148] Empagliflozin (heart failure) - Addendum to Commission A21-93
Last updated 06.01.2022
Project no.:
A21-148
Commission:
Commission awarded on 23.11.2021 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Heart and circulation
Indication:
Adults with symptomatic chronic heart failure with reduced ejection fraction
Result of dossier assessment:
Unchanged after addendum:
Hint of non-quantifiable added benefit
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A21-93 | Empagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2022-01-06 A G-BA decision was published.